廣聯達(002410.SZ):擬參投廣州廣建科創業投資基金
格隆匯2月19日丨廣聯達(002410.SZ)公佈,為推動廣聯達科技股份有限公司技術進步和業務拓展,公司擬通過全資企業北京廣聯達創元投資中心(有限合夥)(簡稱“創元投資”)投資廣州廣建科創業投資基金合夥企業(簡稱“廣州基金”或“合夥企業”),並於2025年2月19日簽署了相關合夥協議。該合夥企業重點投資於新一代信息技術有關的硬科技領域,聚焦人工智能技術、智能建造、數字科技、綠色低碳等早期企業、中小企業和高新技術企業。目標規模為人民幣4,076萬元。創元投資將作為有限合夥人,以自有資金815萬元認購合夥企業份額,預計佔比20%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.